Pfizer Shares Patient Letter re Voxelotor (Oxybryta®) Withdrawal | National Haemoglobinopathy Panel | NHP Haemoglobinopathy England | Sickle Cell Thalassaemia | Rare Inherited Anaemia UK | NHP Haemoglobinopathy England | Sickle Cell Thalassaemia | Rare Inherited Anaemia UK

posted 21st October 2024

Posted 2 years ago

By Pfizer

Publications New Therapies Features Patient Guidelines

21.10.2024
Pfizer shared patient advice regarding their Immediate withdrawal of voxelotor (Oxybryta®).

The NHP distributed this to their network to be shared with patients across England.

Click to view document